Septerna Announces Selection Of SEP-204 As Potential Development Candidate For Treatment Of Graves’ Disease And TED; Reports Initial Preclinical Data Ahead Of Poster Presentation At 2026 ATA Annual Meeting
Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpointsFavorable PK profile anticipated to support once-daily oral dosing in humansPhase 1 clinical trial
Share
Why It Matters
Septerna picked a new medicine called SEP-204 to test in sick people. The early lab work looks good, so watch if their real human tests go well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.